Login to Your Account

Other News To Note

Monday, October 22, 2012

• Durata Therapeutics Inc., of Morristown, N.J., reported in vitro data that could help support a clinical program testing antibiotic candidate dalbavancin in pneumonia. In the study, lung surfactant did not have a significant impact on the in vitro susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to dalbavancin. Results were presented at IDWeek in San Diego.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription